Igniting the slow burn of post-COVID conditions-Reference-Cited by-同舟云学术

Igniting the slow burn of post-COVID conditions

Published:2023-10-31 Issue:5 Volume:14 Page:
ISSN:2150-7511
Container-title:mBio
language:en
Short-container-title:mBio

Author:

Henderson Jeffrey P.¹²^ORCID

Affiliation:

1. Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine , St. Louis, Missouri, USA

2. Center for Women’s Infectious Disease Research, Washington University School of Medicine , St. Louis, Missouri, USA

Abstract

ABSTRACT Post-COVID conditions (PCCs) are persistent new patient symptoms occurring after acute COVID-19 infection and are an increasingly appreciated dimension of the COVID-19 pandemic. The factors that cause PCCs are not well understood. In recent work, Gebo et al. identify a connection between acute IL-6 levels, early COVID-19 convalescent plasma (CP) administration, and later PCCs in subjects from a randomized controlled trial of acutely ill subjects enrolled in 2020 to 2021 (K. A. Gebo, S. L. Heath, Y. Fukuta, X. Zhu, et al., mBio e00618-23, 2023, https://doi.org/10.1128/mbio.00618-23 ). These results may be viewed as part of an emerging picture linking the intensity of inflammatory responses during acute infection to later PCCs.

Funder

HHS | National Institutes of Health

Longer Life Foundation

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mbio.01489-23

Reference20 articles.

1. A clinical case definition of post-COVID-19 condition by a Delphi consensus

2. Centers for Disease Control and Prevention . 2023. Long COVID or post-COVID conditions. Accessed 16 June 2023. Available from: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/

3. Pathogenesis of COVID-19 from the Perspective of the Damage-Response Framework

4. Early antibody treatment, inflammation, and risk of post-COVID conditions

5. Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG